Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05205551
Other study ID # 21-054-TRP
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date October 1, 2021
Est. completion date June 30, 2027

Study information

Verified date March 2024
Source Natera, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The ProTECT registry is an observational longitudinal, multi-center study observing patients undergoing heart transplant for whom Prospera testing is part of routine clinical care, who are enrolled within 60 days of heart transplantation.


Description:

The ProTECT registry is an observational longitudinal, multi-center study observing patients undergoing heart transplant for whom Prospera™ testing is part of routine clinical care, who are enrolled within 60 days of heart transplantation. Patients who are enrolled in this study should have blood drawn for Prospera™ testing at regular intervals per routine clinical care. Prospera™ test results and results of surveillance endomyocardial biopsies, laboratory testing, echocardiograms, angiography and hemodynamic monitoring performed to monitor cardiac status and for signs of transplant rejection, as well as medications and post-transplant re-vascularization and surgical procedures will be recorded in the electronic case report form (eCRF). Patient management decisions, even those informed by the Prospera™ test result, are made based on the individual judgment of the healthcare providers participating in the study.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 411
Est. completion date June 30, 2027
Est. primary completion date October 31, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Patients must meet all the following criteria to be eligible for the study: 1. Age 18 or older at the time of informed consent. 2. Enrolled within 60 days following heart transplantation. 3. Prospera™ testing is planned as part of standard clinical care to monitor for and assess transplant rejection. 4. Prospera™ testing is planned to be performed within 60 days (inclusive) following heart transplantation. 5. Selected by their healthcare provider to receive or continue receiving Prospera™ testing as part of their routine transplant management. 6. Willing and able to provide written informed consent. 7. Willing and able to comply with study procedures. Patients are not eligible for the study if they meet any of the following criteria: 1. Pregnant at the time of signing informed consent. 2. Candidate for multiple solid organ or tissue transplant. 3. History of prior organ or cellular transplantation. 4. Ongoing testing with another allograft dd-cfDNA assessment is planned.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States Natera San Carlos California

Sponsors (1)

Lead Sponsor Collaborator
Natera, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Primary Endpoints: Primary molecular endpoint: percent of donor-derived cell-free DNA (dd-cfDNA) measured via the Prospera™ test.
Primary clinical endpoints:
Biopsy-proven rejection (ISHLT Grade ACR >1R and ISHLT Grade AMR >0).
Rejection with hemodynamic compromise (ejection fraction <40% or >20% decline from baseline or the need for inotropic agents in the absence of biopsy-proven rejection).
Treated rejection (biopsy proven rejection or hemodynamic compromise rejection where immunosuppressive therapy was increased or augmented).
3 years
Secondary Secondary Endpoints The secondary endpoints are:
The predictive performance of the Prospera™ test in detecting rejection or allograft dysfunction after heart transplant as measured by the sensitivity, specificity, negative predictive value, positive predictive value, and area under the curve (AUC) of the Prospera™ test
Acute cellular rejection (ISHLT 2004 grade >1R)
Antibody mediated rejection (ISHLT 2013 grade >0)
Left ventricular ejection fraction (LVEF) measured by echocardiographic assessment
Cardiac allograft vasculopathy (ISHLT grade >0)
Cumulative mean fluorescence intensity (MFI) of donor specific antibodies
3 years
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05732779 - Mobile Video Directly Observed Therapy (DOT) for Immunosuppression Medication Adherence in Adolescent Heart Transplant Recipients N/A
Active, not recruiting NCT05064462 - TTV Viral Load in Heart Transplant Recipients
Recruiting NCT04973943 - Donor-derived Cell Free DNA as a New Biomarker in Cardiac Acute Rejection
Completed NCT03477383 - A New Biomarker for the Non-invasive Diagnosis of Rejection After Heart Transplantation
Not yet recruiting NCT05772442 - Cardiac Transplant Metabolomics With and Without Rejection
Recruiting NCT04707872 - Trifecta-Heart cfDNA-MMDx Study
Recruiting NCT06064123 - Biomarkers for Diagnosis, Prognosis, and Targeted Therapy After Heart Transplantation
Active, not recruiting NCT04921774 - Research on Patients With Heart Transplantation
Recruiting NCT04226521 - Extracorporeal Photopheresis and Early Cardiac Graft Vasculopathy N/A
Completed NCT03393793 - HEart trAnsplantation Registry of piTie-Salpetriere University Hospital
Completed NCT01136135 - Cardiac Magnetic Resonance Imaging (CMRI) for Detection of Cardiac Transplant Rejection N/A
Completed NCT03833050 - The TOGETHER Project - Heart
Active, not recruiting NCT03373227 - Phase II Study Evaluating the Efficacy of Tacrolimus Extended Release Tablets to Twice Daily Tacrolimus Dosing Regimen Phase 2
Active, not recruiting NCT03695601 - Surveillance HeartCare® Outcomes Registry
Active, not recruiting NCT01397812 - Heartsbreath Test for Heart Transplant Rejection N/A
Active, not recruiting NCT05184426 - MuLtimodality EvaluatiOn of aNtibody mEdiated Damage in Heart Transplantation (LEONE-HT)